Cyclogenix has entered into license and research agreements with Wyeth and IMBcom, The University of Queensland’s (UQ) company for commercializing technology from the Institute for Molecular Bioscience (IMB).   Cyclogenix has granted Wyeth exclusive rights to its drug discovery technology platform for generating therapeutic peptides. Wyeth will fund research activities focused on using these technologies and has an option to acquire all rights to these technologies at the end of the research c...